An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects
Author:
Affiliation:
1. Astellas Pharma Europe; Leiden The Netherlands
2. PharmAspire Consulting; Wijchen The Netherlands
Funder
Astellas Pharma
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA;Andersson;Ther Clin Risk Manag,2013
2. Pharmacology: on the mode of action of mirabegron;Andersson;Nat Rev Urol,2016
3. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study;Malik;Clin Pharmacol Ther,2012
4. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women;Krauwinkel;Clin Ther,2012
5. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder;Chapple;Eur Urol,2013
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Examining the Safety of Mirabegron: An Analysis of Real-World Pharmacovigilance Data from the US FDA Adverse Event Reporting System (FAERS) Database;2024-01-03
2. Comparison of Efficacy and Safety of a Combination of Tamsulosin and Mirabegron versus Tamsulosin Alone in the Management of Overactive Bladder in Males with Lower Urinary Tract Symptoms – TAME-Overactive Bladder: An Open-labeled Randomized Controlled Trial;International Journal of Applied & Basic Medical Research;2023
3. Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder;Medicina;2022-06-19
4. Oxytocin as a potential pharmacological tool to combat obesity;Journal of Neuroendocrinology;2022-02-22
5. Mirabegron Ameliorated Atherosclerosis of ApoE−/− Mice in Chronic Intermittent Hypoxia but Not in Normoxia;Cardiovascular Drugs and Therapy;2021-06-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3